Vir Bio Stock (NASDAQ:VIR)
Previous Close
$7.49
52W Range
$7.12 - $13.09
50D Avg
$7.75
200D Avg
$9.21
Market Cap
$1.27B
Avg Vol (3M)
$781.32K
Beta
0.46
Div Yield
-
VIR Company Profile
Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; and VIR-1111 for the prevention of human immunodeficiency virus. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited and Brii Biosciences Offshore Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with The Rockefeller University and MedImmune, Inc.; collaboration with WuXi Biologics and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals SA. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. for the manufacture of SARS-COV-2 antibodies; and clinical collaboration with Gilead Sciences, Inc. for chronic hepatitis B virus. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California.
VIR Performance
Peer Comparison
Ticker | Company |
---|---|
AKRO | Akero Therapeutics, Inc. |
PTCT | PTC Therapeutics, Inc. |
BPMC | Blueprint Medicines Corporation |
DAWN | Day One Biopharmaceuticals, Inc. |
CVAC | CureVac N.V. |
TERN | Terns Pharmaceuticals, Inc. |
VKTX | Viking Therapeutics, Inc. |
KRYS | Krystal Biotech, Inc. |
KRTX | Karuna Therapeutics, Inc. |
MDGL | Madrigal Pharmaceuticals, Inc. |
AMLX | Amylyx Pharmaceuticals, Inc. |